Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 3/20 | 0.41 |
| ▸ | MGAM | O43451 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | SI | P14410 | 2/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 7/20 | 0.38 |
| ▸ | PIM1 | P11309 | 5/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7514024 | 1.00 | IGF1R (0.41) | IGF1RMGAMGAASIMGAM2 | |
| SCHEMBL7514695 | 0.90 | IGF1R (0.40) | IGF1RMGAMGAASIMGAM2 | |
| SCHEMBL7514689 | 0.90 | IGF1R (0.40) | IGF1RMGAMGAASIMGAM2 | |
| SCHEMBL7510586 | 0.89 | IGF1R (0.44) | IGF1RMGAMGAASIMGAM2 | |
| SCHEMBL7510588 | 0.89 | IGF1R (0.44) | IGF1RMGAMGAASIMGAM2 | |
| SCHEMBL7520438 | 0.81 | IGF1R (0.43) | IGF1RMGAMGAASIMGAM2 | |
| SCHEMBL7520443 | 0.81 | IGF1R (0.43) | IGF1RMGAMGAASIMGAM2 | |
| SCHEMBL7519434 | 0.81 | MGAM (0.55) | IGF1RMGAMGAASIMGAM2 | |
| SCHEMBL7519438 | 0.81 | MGAM (0.55) | IGF1RMGAMGAASIMGAM2 | |
| SCHEMBL7519482 | 0.79 | IGF1R (0.44) | IGF1RMGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6452014-B1 | THIAZOLIDINEDIONE COMPOUNDS | GERON CORPORATION | 2002-09-17 | — | — | US | disclosed |
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| WO-2002051409-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | TERT, TERF2, POT1 | IGF1R 1097/4885MGAM 3441/4885GAA 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.